Equities

ImmuPharma PLC

IMM:LSE

ImmuPharma PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2.16
  • Today's Change-0.009 / -0.41%
  • Shares traded237.12k
  • 1 Year change-7.45%
  • Beta2.5435
Data delayed at least 20 minutes, as of Jul 02 2024 15:43 BST.
More ▼

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.210.671.65
Total Receivables, Net0.691.341.13
Total Inventory------
Prepaid expenses0.020.070.05
Other current assets, total0.430.250.51
Total current assets1.342.343.35
Property, plant & equipment, net0.100.390.35
Goodwill, net------
Intangibles, net0.450.470.48
Long term investments0.640.691.42
Note receivable - long term------
Other long term assets0.180.080.41
Total assets2.723.976.00
LIABILITIES
Accounts payable0.781.071.16
Accrued expenses0.890.380.43
Notes payable/short-term debt00.000.00
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities1.671.451.58
Total long term debt000
Total debt00.000.00
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities1.671.451.58
SHAREHOLDERS EQUITY
Common stock302928
Additional paid-in capital292927
Retained earnings (accumulated deficit)(57)(54)(50)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(1.26)(1.27)(1.34)
Total equity1.062.524.41
Total liabilities & shareholders' equity2.723.976.00
Total common shares outstanding416333285
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.